In conjunction with Triple Negative Breast Cancer Day, HemOnc Today presents five updates in the treatment of triple-negative breast cancer and on associated disparities that may impact your practice.
Triple Negative Breast Cancer Day — recognized annually on March 3 — is a global awareness and grassroots fundraising campaign initiated by the Triple Negative Breast Cancer Foundation.
In conjunction with Triple Negative Breast Cancer Day, HemOnc Today presents five updates in the treatment of triple-negative breast cancer, as well as on disparities associated with its incidence, that may impact your practice.
- The combination of mifepristone and eribulin appeared active in women with recurrent, glucocorticoid receptor–positive triple-negative breast cancer, Sharon Wilks, MD, FACP, told HemOnc Today at the San Antonio Breast Cancer Symposium. Watch here.
- Mitochondrial DNA testing may identify genetic ancestry that is discordant from self-identified ethnicity in patients with triple-negative breast cancer, according to study results published in Cancer. Read more.
- Debu Tripathy, MD, spoke with HemOnc Today at the San Antonio Breast Cancer Symposium about the I-SPY 2 trial, which showed the addition of veliparib (ABT-888, AbbVie) and carboplatin to standard neoadjuvant therapy improved pathological complete response among women with triple-negative breast cancer. Watch here.
- Black women with triple-negative breast cancer appeared more likely to lack the androgen receptor protein compared with white women, which may contribute to the racial disparity observed among black women with this disease. Read more.
- Antoinette Tan, MD, MHS, discusses the significant unmet need for patients with metastatic triple-negative breast cancer, as there currently are no targeted therapies approved for this patient population. Watch here.